<SEC-DOCUMENT>0001104659-24-090153.txt : 20240815
<SEC-HEADER>0001104659-24-090153.hdr.sgml : 20240815
<ACCEPTANCE-DATETIME>20240815170013
ACCESSION NUMBER:		0001104659-24-090153
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		17
CONFORMED PERIOD OF REPORT:	20240731
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20240815
DATE AS OF CHANGE:		20240815

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Armata Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0000921114
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				911549568
		STATE OF INCORPORATION:			WA
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37544
		FILM NUMBER:		241213242

	BUSINESS ADDRESS:	
		STREET 1:		5005 MCCONNELL AVE
		CITY:			LOS ANGELES
		STATE:			CA
		ZIP:			90066
		BUSINESS PHONE:		310-665-2928

	MAIL ADDRESS:	
		STREET 1:		5005 MCCONNELL AVE
		CITY:			LOS ANGELES
		STATE:			CA
		ZIP:			90066

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AmpliPhi Biosciences Corp
		DATE OF NAME CHANGE:	20130222

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	TARGETED GENETICS CORP /WA/
		DATE OF NAME CHANGE:	19940331
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>tm2421653d1_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:us-roles="http://fasb.org/us-roles/2023" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:armp="http://armatapharma.com/20240731">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02C_US%2DGAAP%2D2023 -->
<!-- Field: Set; Name: xdx; ID: xdx_038_armp_armatapharma.com_20240731 -->
<!-- Field: Set; Name: xdx; ID: xdx_048_20240731_20240731 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_058_edei%2D%2DEntityCentralIndexKey_0000921114 -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="AsOf2024-07-31" id="Fact000003" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="AsOf2024-07-31" id="Fact000004" name="dei:EntityCentralIndexKey">0000921114</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="armp-20240731.xsd" xlink:type="simple"/>
  </ix:references>
 <ix:resources>
    <xbrli:context id="AsOf2024-07-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000921114</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-31</xbrli:startDate>
        <xbrli:endDate>2024-07-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 2pt solid; border-bottom: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="margin: 0">&#160;</p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>UNITED STATES</b></p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SECURITIES AND EXCHANGE COMMISSION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Washington, D.C. 20549</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>FORM <span id="xdx_90A_edei--DocumentType_c20240731__20240731_zyP9v2RuYD9e"><ix:nonNumeric contextRef="AsOf2024-07-31" id="Fact000009" name="dei:DocumentType">8-K</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CURRENT REPORT</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Pursuant to Section&#160;13 OR 15(d) of
The Securities Exchange Act of 1934</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Date of Report (Date of earliest event reported):
<span id="xdx_90D_edei--DocumentPeriodEndDate_c20240731__20240731_zNMIBDfs7Jta"><ix:nonNumeric contextRef="AsOf2024-07-31" format="ixt:datemonthdayyearen" id="Fact000010" name="dei:DocumentPeriodEndDate">July 31, 2024</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="border-bottom: Black 1pt solid; font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><b><span id="xdx_90A_edei--EntityRegistrantName_c20240731__20240731_zGKMcyGKbzs2"><ix:nonNumeric contextRef="AsOf2024-07-31" id="Fact000011" name="dei:EntityRegistrantName">ARMATA PHARMACEUTICALS, INC.</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact name of registrant as specified in
its charter)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="border-bottom: Black 1pt solid; width: 33%; text-align: center"><span style="font-size: 10pt"><b><span id="xdx_90B_edei--EntityIncorporationStateCountryCode_c20240731__20240731_zyfHbycSZyzc"><ix:nonNumeric contextRef="AsOf2024-07-31" format="ixt-sec:stateprovnameen" id="Fact000012" name="dei:EntityIncorporationStateCountryCode">Washington</ix:nonNumeric></span></b></span></td>
    <td style="padding-bottom: 1pt; width: 1%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 33%; text-align: center"><span style="font-size: 10pt"><b><span id="xdx_904_edei--EntityFileNumber_c20240731__20240731_zBwKPCMKZeW1"><ix:nonNumeric contextRef="AsOf2024-07-31" id="Fact000013" name="dei:EntityFileNumber">001-37544</ix:nonNumeric></span></b></span></td>
    <td style="padding-bottom: 1pt; width: 1%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 32%; text-align: center"><span style="font-size: 10pt"><b><span id="xdx_90C_edei--EntityTaxIdentificationNumber_c20240731__20240731_zKre579PhODe"><ix:nonNumeric contextRef="AsOf2024-07-31" id="Fact000014" name="dei:EntityTaxIdentificationNumber">91-1549568</ix:nonNumeric></span></b></span></td></tr>
<tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-size: 10pt">(State or other jurisdiction<br/>
 of incorporation)</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">(Commission File Number)</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">(IRS Employer<br/>
 Identification No.)</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
<td style="border-bottom: Black 1pt solid; text-align: center; width: 49%; padding-right: 5.4pt; padding-left: 5.4pt"><span id="xdx_90A_edei--EntityAddressAddressLine1_c20240731__20240731_zXUf4kSCDzW8"><b><ix:nonNumeric contextRef="AsOf2024-07-31" id="Fact000015" name="dei:EntityAddressAddressLine1">5005 McConnell Avenue</ix:nonNumeric></b></span><b>,</b> <b><span id="xdx_902_edei--EntityAddressCityOrTown_c20240731__20240731_ze0h9wtG1Q7h"><ix:nonNumeric contextRef="AsOf2024-07-31" id="Fact000016" name="dei:EntityAddressCityOrTown">Los Angeles</ix:nonNumeric></span></b><b>, <span id="xdx_905_edei--EntityAddressStateOrProvince_c20240731__20240731_zzXdbf99c75e"><ix:nonNumeric contextRef="AsOf2024-07-31" format="ixt-sec:stateprovnameen" id="Fact000017" name="dei:EntityAddressStateOrProvince">California</ix:nonNumeric></span></b></td>
    <td style="padding-bottom: 1pt; width: 2%">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: center; width: 49%; padding-right: 5.4pt; padding-left: 5.4pt"><b></b> <b><span id="xdx_908_edei--EntityAddressPostalZipCode_c20240731__20240731_zn7CCLS2Qqd4"><ix:nonNumeric contextRef="AsOf2024-07-31" id="Fact000018" name="dei:EntityAddressPostalZipCode">90066</ix:nonNumeric></span></b></td></tr>
<tr style="vertical-align: top">
<td style="padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt; text-align: center"><span style="font-size: 10pt">(Address of principal executive offices)</span></td>
    <td>&#160;</td>
<td style="padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt; text-align: center"><span style="font-size: 10pt">(Zip Code)</span></td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(<span id="xdx_904_edei--CityAreaCode_c20240731__20240731_z3a97fzmvzD2"><ix:nonNumeric contextRef="AsOf2024-07-31" id="Fact000019" name="dei:CityAreaCode">310</ix:nonNumeric></span>) <span id="xdx_906_edei--LocalPhoneNumber_c20240731__20240731_zF4Sa1SMGXBd"><ix:nonNumeric contextRef="AsOf2024-07-31" id="Fact000020" name="dei:LocalPhoneNumber">655-2928</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Registrant&#8217;s telephone number, including area code)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="border-top: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Former name or former address, if changed since last report)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 24px; font-size: 10pt"><span style="font-family: Wingdings"><span id="xdx_90F_edei--WrittenCommunications_c20240731__20240731_zDdjBx2O7MHj"><ix:nonNumeric contextRef="AsOf2024-07-31" format="ixt:booleanfalse" id="Fact000021" name="dei:WrittenCommunications">&#168;</ix:nonNumeric></span></span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-family: Wingdings"><span id="xdx_908_edei--SolicitingMaterial_c20240731__20240731_zjLDlwsU4qvd"><ix:nonNumeric contextRef="AsOf2024-07-31" format="ixt:booleanfalse" id="Fact000022" name="dei:SolicitingMaterial">&#168;</ix:nonNumeric></span></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-family: Wingdings"><span id="xdx_90A_edei--PreCommencementTenderOffer_c20240731__20240731_zPpQ2RatP7N2"><ix:nonNumeric contextRef="AsOf2024-07-31" format="ixt:booleanfalse" id="Fact000023" name="dei:PreCommencementTenderOffer">&#168;</ix:nonNumeric></span></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-family: Wingdings"><span id="xdx_901_edei--PreCommencementIssuerTenderOffer_c20240731__20240731_z5VLNLZuuPeg"><ix:nonNumeric contextRef="AsOf2024-07-31" format="ixt:booleanfalse" id="Fact000024" name="dei:PreCommencementIssuerTenderOffer">&#168;</ix:nonNumeric></span></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Emerging Growth Company&#160;<span style="font-family: Wingdings"><span id="xdx_909_edei--EntityEmergingGrowthCompany_c20240731__20240731_zo82aLyKlxvl"><ix:nonNumeric contextRef="AsOf2024-07-31" format="ixt:booleanfalse" id="Fact000025" name="dei:EntityEmergingGrowthCompany">&#168;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act.&#160;<span style="font-family: Wingdings">&#168;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Securities registered pursuant to Section&#160;12(b)&#160;of
the Act:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; width: 31%; padding-right: 1.5pt; padding-left: 1.5pt; text-align: center"><span style="font-size: 10pt"><b>Title
    of each class</b></span></td>
    <td style="vertical-align: bottom; width: 1%; padding-right: 1.5pt; padding-left: 1.5pt; text-align: center"><b>&#160;</b></td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; width: 30%; padding-right: 1.5pt; padding-left: 1.5pt; text-align: center"><span style="font-size: 10pt"><b>Trading
    Symbol(s)</b></span></td>
    <td style="vertical-align: bottom; width: 1%; padding-right: 1.5pt; padding-left: 1.5pt; text-align: center"><b>&#160;</b></td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; width: 37%; padding-right: 1.5pt; padding-left: 1.5pt; text-align: center"><span style="font-size: 10pt"><b>Name
    of each exchange on which registered</b></span></td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding-right: 1.5pt; padding-left: 1.5pt; text-align: center"><span style="font-size: 10pt"><span id="xdx_90B_edei--Security12bTitle_c20240731__20240731_z72QPTdsxh89"><ix:nonNumeric contextRef="AsOf2024-07-31" id="Fact000026" name="dei:Security12bTitle">Common Stock</ix:nonNumeric></span></span></td>
    <td style="padding-right: 1.5pt; padding-left: 1.5pt; text-align: center">&#160;</td>
    <td style="padding-right: 1.5pt; padding-left: 1.5pt; text-align: center"><span style="font-size: 10pt"><span id="xdx_907_edei--TradingSymbol_c20240731__20240731_ziEpKVNQHmJ"><ix:nonNumeric contextRef="AsOf2024-07-31" id="Fact000027" name="dei:TradingSymbol">ARMP</ix:nonNumeric></span></span></td>
    <td style="padding-right: 1.5pt; padding-left: 1.5pt; text-align: center">&#160;</td>
    <td style="padding-right: 1.5pt; padding-left: 1.5pt; text-align: center"><span style="font-size: 10pt"><span id="xdx_90F_edei--SecurityExchangeName_c20240731__20240731_zaRsnXvMGwzg"><ix:nonNumeric contextRef="AsOf2024-07-31" format="ixt-sec:exchnameen" id="Fact000028" name="dei:SecurityExchangeName">NYSE American</ix:nonNumeric></span></span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1pt solid; border-bottom: Black 2pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0px">&#160;</td>
    <td style="width: 72px; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item 5.02</b></span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(b)&#160;and (c)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July&#160;31, 2024, Armata Pharmaceuticals,&#160;Inc.
(the &#8220;<i>Company</i>&#8221;) entered into an employment letter agreement (the &#8220;<i>Agreement</i>&#8221;) with David House,
pursuant to which he has agreed to serve as the Company&#8217;s Senior Vice President, Finance, effective August&#160;16, 2024 (the &#8220;<i>Effective
Date</i>&#8221;). On August&#160;15, 2024, the Company announced Mr.&#160;House&#8217;s appointment as Senior Vice President, Finance
in the press release furnished hereto as Exhibit&#160;99.1. The Company delayed the filing of this Current Report on Form&#160;8-K until
the date on which the Company made a public announcement of such appointment pursuant to the instruction to Item 5.02(c)&#160;of Form&#160;8-K.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Before joining the Company, Mr.&#160;House, age
40, served as Corporate Controller and Vice President of Accounting at ZO Skin Health,&#160;Inc., a multi-channel physician-dispensed
skincare company, from October&#160;2018 to May&#160;2024. At ZO Skin Health, he led global accounting operations, managed financial reporting,
and played a crucial role in the company&#8217;s acquisition by Blackstone. He also established international subsidiaries and oversaw
financial integration for mergers and acquisitions. Mr.&#160;House&#8217;s experience includes similar financial leadership roles at Peregrine
Pharmaceuticals,&#160;Inc., a clinical-stage biopharmaceutical company, and Avid Bioservices,&#160;Inc. (CDMO), a contract development
and manufacturing organization where he served as Controller and was responsible for implementing ASC 606, managing technical accounting,
and conducting Securities and Exchange Commission (the &#8220;<i>SEC</i>&#8221;) reporting. His career also includes roles at Viant,&#160;Inc.
(DSP), Sourcing Solutions, LLC, and Apria Healthcare (APR), where he held various accounting and financial management positions. In the
early stages of his career, Mr.&#160;House worked as a Senior Auditor at Windes, a public accounting firm. There, he managed comprehensive
audits for public, private, and not-for-profit entities and contributed to SEC filings and internal control evaluations. Mr.&#160;House
holds a Bachelor of Arts in Business Administration with an Accounting concentration from California State University, Fullerton. He obtained
his California Certified Public Accountant license on January&#160;5, 2011, which is currently inactive.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Agreement with Mr.&#160;House, pursuant to
which he has agreed to serve as the Company&#8217;s Senior Vice President, Finance, provides for an initial annual base salary of $350,000,
with a target annual bonus opportunity equal to 40% of his base salary, with the actual bonus payable in respect of any fiscal year dependent
on actual performance as determined by the Company&#8217;s board of directors or compensation committee. As soon as practicable following
the Agreement&#8217;s effective date, Mr.&#160;House will be granted an option under the Company&#8217;s 2016 Equity Incentive Plan (the
&#8220;<i>Plan</i>&#8221;) to purchase 75,000 shares of the Company&#8217;s common stock, which will vest, conditioned upon his continuous
service, in equal annual installments on the first four anniversaries of the date of grant (the &#8220;<i>Option</i>&#8221;). The per
share exercise price of the Option will be the fair market value of the Company&#8217;s common stock on the date of grant in accordance
with the Plan. Mr.&#160;House will also be eligible to participate in the benefits programs made available by the Company to its senior
executives.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Agreement provides that if the Company terminates
Mr.&#160;House&#8217;s employment other than for &#8220;cause&#8221; (as defined in the Agreement), or Mr.&#160;House terminates his employment
for &#8220;good reason&#8221; (as defined in the Agreement), then, subject to his execution of a release and compliance with his restrictive
covenants, he will be entitled to (i)&#160;a continuation of his then-current base salary for six months (or 12 months if such termination
occurs during the CIC Protection Period, which is defined as the period commencing one month prior to and ending 12 months following a
&#8220;change in control&#8221; (as defined in the Agreement)) and (ii)&#160;payment of COBRA premiums for up to 12 months if such termination
occurs during the CIC Protection Period. In addition, if such termination occurs during the CIC Protection Period, all unvested equity
awards held by Mr.&#160;House that are subject to time-based vesting requirements will vest in full in connection with such termination.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin-top: 0pt; margin-bottom: 0pt; text-align: center; font-size: 10pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --> -</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There is no arrangement
or understanding between Mr.&#160;House and any other persons pursuant to which Mr.&#160;House was selected as principal financial officer.
There are also no family relationships between Mr.&#160;House and any of the Company&#8217;s directors or executive officers, and he has
no direct or indirect material interest in any transaction that would be required to be disclosed under Item 404(a)&#160;of Regulation
S-K.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of the Effective
Date, Mr.&#160;House will be the Company&#8217;s principal financial officer, a role that he will assume from the Company&#8217;s current
principal financial officer, Richard Rychlik, who will continue in his role as the Company&#8217;s Vice President, Corporate Controller.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The foregoing
description of the Agreement does not constitute a complete summary of the terms of the Agreement and is qualified in its entirety by
reference to the full text of the Agreement, which is filed as Exhibit&#160;10.1 to this Current Report on Form&#160;8-K and incorporated
herein by reference.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item 9.01. Financial Statements and Exhibits.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;Exhibits</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top; background-color: white">
    <td><a href="tm2421653d1_ex99-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</span></a></td>
    <td style="width: 89%"><a href="tm2421653d1_ex99-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Press release, dated August&#160;15, 2024. </span></a></td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td><a href="tm2421653d1_ex10-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</span></a></td>
    <td><a href="tm2421653d1_ex10-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Employment Letter Agreement, dated July&#160;31, 2024, by and between Armata Pharmaceuticals,&#160;Inc. and David House.</span></a></td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">104</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Cover Page&#160;Interactive Data File (embedded within XBRL document)</span></td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b></b></p>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin-top: 0pt; margin-bottom: 0pt; text-align: center; font-size: 10pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --> -</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SIGNATURES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: August&#160;15, 2024</span></td>
    <td colspan="2" style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Armata Pharmaceuticals,&#160;Inc.</span></td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td colspan="2">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="width: 50%">&#160;</td>
    <td style="width: 5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By: </span></td>
    <td style="border-bottom: black 1pt solid; width: 45%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Deborah L. Birx</span></td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deborah L. Birx, M.D.</span></td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer </span></td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal Executive Officer)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --> -</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFjV0KwjAQhE/QOyx5ltrGX/po0SJWkSLia7BbCbbZsol/R/KWxhZxWViWmW9GiIHIaKVrZDgtihwO2LS1cggFVshozugd6XqTgL8FXrR1rIzr3h+YkmfQM5NQjpQXOutdWywTiObDeDyUY4imiZzBfiuCr56SqXSJxmlVgzIl7Jla1ugUv/qEg3qSoebVVR2RrSaTQBxGvfwGGcUSdnRXD+KrhTxPRTDoJhAZ0631ruXTofmSsKyx8XW2p/8bfAALtkqV -->
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>tm2421653d1_ex10-1.htm
<DESCRIPTION>EXHIBIT 10.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: right; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit 10.1</B></FONT></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;<IMG SRC="tm2421653d1_ex10-1img001.jpg" ALT=""></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;Armata Pharmaceuticals,&nbsp;Inc.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">5005 McConnell Ave.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Los Angeles, CA 90066</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">July&nbsp;29, 2024</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dear David:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are pleased to confirm our offer of employment
with Armata Pharmaceuticals,&nbsp;Inc. (the &ldquo;<U>Company</U>&rdquo;) in the position of Senior Vice President, Finance, effective
16 August&nbsp;2024, (the &ldquo;<U>Effective Date</U>&rdquo;) on the terms set forth in this letter agreement (the &ldquo;<U>Agreement</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>1.</B></FONT><B>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt; color: #333333">Position</FONT></B><FONT STYLE="color: #333333; font-size: 10pt">.
As Senior Vice President, Finance, you will be responsible for overseeing all the financial affairs of the Company and supervising the
Controller and finance team.&nbsp; You</FONT> <FONT STYLE="font-size: 10pt">will report directly to the Chief Executive Officer of the
Company. You will be the Principal Financial Officer for SEC reporting. You agree to devote your full business time and attention to
your work for the Company. Except upon the prior written consent of the Board of the Directors of the Company (the &ldquo;<U>Board</U>&rdquo;),
you will not, during your employment with the Company, (i)&nbsp;accept or maintain any other employment, or (ii)&nbsp;engage, directly
or indirectly, in any other business activity (whether or not pursued for pecuniary advantage) that might interfere with your duties
and responsibilities as a Company employee or create a conflict of interest with the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>2.</B></FONT><B>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Salary</FONT></B><FONT STYLE="font-size: 10pt">.
Effective as of 16 August, 2024 your base salary will be paid at the annualized rate of $350,000 per year on the Company&rsquo;s regular
payroll dates and subject to approved deductions and required withholdings. Your salary will be reviewed from time to time by the Board
or its compensation committee and may be adjusted in the sole discretion of the Board or its compensation committee.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>3.</B></FONT><B>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Bonus</FONT></B><FONT STYLE="font-size: 10pt">.
You will be eligible to earn an annual performance bonus based on achievement of Company performance objectives to be established by the
Board or its compensation committee and provided to you. Your annual target performance bonus will initially be equal to 40% of your base
salary, although the amount of any payment will be dependent upon actual performance as determined by the Board or its compensation committee.
You must be employed by the Company through the last day of the fiscal year for which bonuses are paid in order to be eligible to receive
a bonus. Your annual performance bonus, if any, shall be paid to you on or before March&nbsp;15 of the year following the year to which
it relates. Your annual target performance bonus percentage is subject to modification from time to time in the discretion of the Board
or its compensation committee.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>4.</B></FONT><B>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Equity
Award</FONT></B><FONT STYLE="font-size: 10pt">. As soon as practicable following the Effective Date, you will be granted an option under
the Company&rsquo;s 2016 Equity Incentive Plan (the &ldquo;<U>Plan</U>&rdquo;) to purchase 75,000 shares of the Company&rsquo;s common
stock (the &ldquo;<U>Option</U>&rdquo;). The Option shall vest over time conditioned upon your continuous service to the Company in equal
annual installments on the first four anniversaries of the date of grant. The exercise price of the Option shall be the fair market value
of the Company&rsquo;s common stock on the date of grant in accordance with the Plan and shall be subject to the terms and conditions
of the Plan, stock option grant notice and option agreement to be entered into between you and the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>5.</B></FONT><B>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Benefits</FONT></B><FONT STYLE="font-size: 10pt">.
You will be eligible to participate in the benefits made generally available by the Company to its senior executives, in accordance with
the benefit plans established by the Company, and as may be amended from time to time in the Company&rsquo;s sole discretion.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>6.</B></FONT><B>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">At-Will
Employment</FONT></B><FONT STYLE="font-size: 10pt">. The Company is an &ldquo;at-will&rdquo; employer. Accordingly, either you or the
Company may terminate the employment relationship at any time, with or without advance notice, and with or without cause.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>7.</B></FONT><B>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Termination</FONT></B><FONT STYLE="font-size: 10pt">.
Upon any termination of your employment, you will be deemed to have resigned, and you hereby resign, from all offices and directorships,
if any, then held by you with the Company or any subsidiary. In the event of termination of your employment with the Company, regardless
of the reasons for such termination, the Company shall pay your base salary and accrued but unused vacation up to and through the date
of termination, less applicable payroll and tax withholdings (the &ldquo;<U>Accrued Obligations</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><B>8.</B></TD><TD STYLE="text-align: justify"><B>Severance</B>. You shall be eligible for the severance benefits described in this Section.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">a.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">In
the event (i)&nbsp;the Company terminates your employment without Cause (as defined below and other than due to your death or disability),
or (ii)&nbsp;you terminate your employment for Good Reason (as defined below), and provided in either case of (i)&nbsp;or (ii)&nbsp;such
termination or resignation constitutes a &ldquo;separation from service&rdquo; (as defined under Treasury Regulation Section&nbsp;1.409A-1(h),
without regard to any alternative definition thereunder, a &ldquo;<U>Separation from Service</U>&rdquo;) (such termination or resignation,
an &ldquo;<U>Involuntary Termination</U>&rdquo;) and such Involuntary Termination does not occur during the CiC Protection Period (as
defined below), then, in addition to the Accrued Obligations, subject to your obligations in Section&nbsp;8(c)&nbsp;below, you shall be
entitled to receive an amount equal to six (6)&nbsp;months of your then current base salary (ignoring any decrease in base salary that
forms the basis for Good Reason), less all applicable withholdings and deductions, paid on the schedule described in Section&nbsp;8(c)&nbsp;below
(the &ldquo;<U>Severance Pay</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">b.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">In
the event that you experience an Involuntary Termination during the period (the &ldquo;<U>CiC Protection Period</U>&rdquo;) commencing
one (1)&nbsp;month prior to the consummation of the first Change in Control (as defined in Section&nbsp;9 below) to occur following the
Effective Date and ending on the date that is twelve (12) months immediately following the consummation of such Change in Control, then,
in addition to the Accrued Obligations and subject to the obligations set forth in Section&nbsp;8(c)&nbsp;below, you shall be entitled
to the following payments and benefits (the &ldquo;<U>CiC Severance Pay</U>&rdquo;): (i)&nbsp;an amount equal to twelve (12) months of
your then-current base salary, less all applicable withholdings and deductions, paid on the schedule described in Section&nbsp;8(c), and
(ii)&nbsp;to the extent permitted by applicable law without any penalty to you or the Company and subject to your timely election of COBRA
continuation coverage under the Company&rsquo;s group health plan, on the first regularly scheduled payroll date of each month for a period
of twelve (12) months (the &ldquo;<U>COBRA Period</U>&rdquo;), the Company will pay, directly to or on your behalf, an amount equal to
the monthly COBRA premium cost for your coverage thereunder; <I>provided</I>, that the payments pursuant to this clause (ii)&nbsp;shall
cease earlier than the expiration of the COBRA Period in the event that, during the COBRA Period, (x)&nbsp;you become eligible to receive
any health benefits, including through a spouse&rsquo;s employer or (y)&nbsp;you are no longer eligible for benefits under COBRA.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">c.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">The
Severance Pay or CiC Severance Pay, as applicable, is conditioned upon (i)&nbsp;your continuing to comply with your obligations under
your PIIA (as defined in Section&nbsp;11) during the period of time in which you are receiving the Severance Pay or CiC Severance Pay,
as applicable; (ii)&nbsp;your delivering to the Company an executed separation agreement and general release of claims in favor of the
Company (the &ldquo;<U>Release</U>&rdquo;), in a form provided by the Company, within the time period set forth therein, which becomes
effective in accordance with its terms, which shall be no later than sixty (60) days following your Separation from Service. The Severance
Pay or CiC Severance Pay, as applicable, will be paid in equal installments on the Company&rsquo;s regular payroll schedule over the period
outlined above following the date of your Separation from Service; provided, however, that no payments will be made prior to the sixtieth
(60<SUP>th</SUP>) day following your Separation from Service. On the sixtieth (60<SUP>th</SUP>) day following your Separation from Service,
the Company will pay you in a lump sum the amount of the Severance Pay that you would have received on or prior to such date under the
original schedule but for the delay while waiting for the sixtieth (60<SUP>th</SUP>) day, with the balance of the Severance Pay being
paid as originally scheduled.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">d.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">&ldquo;<U>Cause</U>&rdquo;
for purposes of your Severance Pay means (i)&nbsp;your gross negligence or willful failure substantially to perform your duties and responsibilities
to the Company or deliberate violation of a Company policy; (ii)&nbsp;your commission of any act of fraud, embezzlement or dishonesty
against the Company or any other willful misconduct that has caused or is reasonably expected to result in material injury to the Company;
(iii)&nbsp;your unauthorized use or disclosure of any proprietary information or trade secrets of the Company or any other party to whom
you owe an obligation of nondisclosure as a result of your relationship with the Company; or (iv)&nbsp;your willful breach of any of your
obligations under any written agreement or covenant with the Company, including without limitation this Agreement and your PIIA (as defined
below).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">e.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">&ldquo;<U>Good
Reason</U>&rdquo; for purposes of your Severance Pay means the occurrence at any time of any of the following without your prior written
consent: (i)&nbsp;a material reduction in your authority, duties or responsibilities (other than a mere change in title following any
merger or consolidation of the Company with another entity); (ii)&nbsp;a material reduction in your base salary; or (iii)&nbsp;any willful
failure or willful breach by the Company of any of its material obligations under this Agreement. For purposes of this subsection, no
act, or failure to act, on the Company&rsquo;s part shall be deemed &ldquo;willful&rdquo; unless done, or omitted to be done, by the Company
not in good faith and without reasonable belief that the Company&rsquo;s act, or failure to act, was in the best interest of the Company.
In order to terminate your employment under this Agreement for Good Reason, you must (1)&nbsp;provide written notice to the Company within
ninety (90) days of the first occurrence of the events described above, (2)&nbsp;allow the Company at least thirty (30) days from such
receipt of such written notice to cure such event, and (3)&nbsp;if such event is not reasonably cured within such period, resign from
all position you then hold with the Company effective not later than the one- hundred eightieth (180<SUP>th</SUP>) day after the initial
occurrence of such event.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>9.</B></FONT><B>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Change
in Control Acceleration</FONT></B><FONT STYLE="font-size: 10pt">. Notwithstanding any other provision contained herein, if your Involuntary
Termination occurs during the CiC Protection Period, then the vesting of all of your outstanding equity awards (including the Option)
that are subject to time-based vesting requirements shall accelerate in full such that all such equity awards shall be deemed fully vested
as of the date of such Involuntary Termination (or Change in Control, if later). For purposes of this Agreement, the term &ldquo;<U>Change
in Control</U>&rdquo; shall have the meaning ascribed to such term in the Plan, except that Innoviva,&nbsp;Inc. and each of its majority-owned
subsidiaries and affiliates shall be considered Legacy Investors (as defined in the Plan) for purposes of determining whether or not a
Change in Control has occurred.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>10.</B></FONT><B>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Taxes</FONT></B><FONT STYLE="font-size: 10pt">.
All amounts paid under this Agreement shall be paid less all applicable state and federal tax withholdings (if any) and any other withholdings
required by any applicable jurisdiction or authorized by you.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">a.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Section&nbsp;409A</U>.
The Severance Pay provided in this Agreement is intended to qualify for an exemption from application of Section&nbsp;409A of the Internal
Revenue Code of 1986, as amended (the &ldquo;<U>Code</U>&rdquo;) and the regulations and other guidance thereunder and any state law of
similar effect (collectively &ldquo;<U>Section&nbsp;409A</U>&rdquo;) or to comply with its requirements to the extent necessary to avoid
adverse personal tax consequences under Section&nbsp;409A, and any ambiguities herein shall be interpreted accordingly. Each installment
of Severance Pay is a separate &ldquo;payment&rdquo; for purposes of Treasury Regulations Section&nbsp;1.409A-2(b)(2)(i), and the Severance
Pay is intended to satisfy the exemptions from application of Section&nbsp;409A provided under Treasury Regulations Sections 1.409A-1(b)(4),
1.409A-1(b)(5)&nbsp;and 1.409A-1(b)(9). However, if such exemptions are not available and you are, upon Separation from Service, a &ldquo;specified
employee&rdquo; for purposes of Section&nbsp;409A, then, solely to the extent necessary to avoid adverse personal tax consequences under
Section&nbsp;409A, the timing of the Severance Pay shall be delayed until the earlier of (i)&nbsp;six (6)&nbsp;months and one day after
your Separation from Service, or (ii)&nbsp;your death. Except to the minimum extent that payments must be delayed because you are a &ldquo;specified
employee&rdquo;, all amounts of Severance Pay will be paid as soon as practicable in accordance with the schedule provided herein and
in accordance with the Company&rsquo;s normal payroll practices.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">b.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Section&nbsp;280G</U>.
If any payment or benefit you will or may receive from the Company or otherwise (a &ldquo;<U>280G Payment</U>&rdquo;) would (i)&nbsp;constitute
a &ldquo;parachute payment&rdquo; within the meaning of Section&nbsp;280G of the Code, and (ii)&nbsp;but for this sentence, be subject
to the excise tax imposed by Section&nbsp;4999 of the Code (the &ldquo;<U>Excise Tax</U>&rdquo;), then any such 280G Payment pursuant
to this Agreement or otherwise (a &ldquo;<U>Payment</U>&rdquo;) shall be equal to the Reduced Amount. The &ldquo;<U>Reduced Amount</U>&rdquo;
shall be either (x)&nbsp;the largest portion of the Payment that would result in no portion of the Payment (after reduction) being subject
to the Excise Tax or (y)&nbsp;the largest portion, up to and including the total, of the Payment, whichever amount (i.e., the amount determined
by clause (x)&nbsp;or by clause (y)), after taking into account all applicable federal, state and local employment taxes, income taxes,
and the Excise Tax (all computed at the highest applicable marginal rate), results in your receipt, on an after-tax basis, of the greater
economic benefit notwithstanding that all or some portion of the Payment may be subject to the Excise Tax. If a reduction in a Payment
is required pursuant to the preceding sentence and the Reduced Amount is determined pursuant to clause (x)&nbsp;of the preceding sentence,
the reduction shall occur in the manner (the &ldquo;<U>Reduction Method</U>&rdquo;) that results in the greatest economic benefit for
you. If more than one method of reduction will result in the same economic benefit, the items so reduced will be reduced pro rata (the
&ldquo;<U>Pro Rata Reduction Method</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Notwithstanding the foregoing,
if the Reduction Method or the Pro Rata Reduction Method would result in any portion of the Payment being subject to taxes pursuant to
Section&nbsp;409A that would not otherwise be subject to taxes pursuant to Section&nbsp;409A, then the Reduction Method and/or the Pro
Rata Reduction Method, as the case may be, shall be modified so as to avoid the imposition of taxes pursuant to Section&nbsp;409A as follows:
(A)&nbsp;as a first priority, the modification shall preserve to the greatest extent possible, the greatest economic benefit for you as
determined on an after-tax basis; (B)&nbsp;as a second priority, Payments that are contingent on future events (e.g., being terminated
without Cause), shall be reduced (or eliminated) before Payments that are not contingent on future events; and (C)&nbsp;as a third priority,
Payments that are &ldquo;deferred compensation&rdquo; within the meaning of Section&nbsp;409A shall be reduced (or eliminated) before
Payments that are not deferred compensation within the meaning of Section&nbsp;409A.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Unless you and the Company
agree on an alternative accounting firm, the accounting firm engaged by the Company for general tax compliance purposes as of the day
prior to the effective date of the change of control transaction triggering the Payment shall perform the foregoing calculations. If the
accounting firm so engaged by the Company is serving as accountant or auditor for the individual, entity or group effecting the change
of control transaction, the Company shall appoint a nationally recognized accounting firm to make the determinations required hereunder.
The Company shall bear all expenses with respect to the determinations by such accounting firm required to be made hereunder. The Company
shall use commercially reasonable efforts to cause the accounting firm engaged to make the determinations hereunder to provide its calculations,
together with detailed supporting documentation, to you and the Company within fifteen (15) calendar days after the date on which your
right to a 280G Payment becomes reasonably likely to occur (if requested at that time by you or the Company) or such other time as requested
by you or the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If you receive a Payment for
which the Reduced Amount was determined pursuant to clause (x)&nbsp;of the first paragraph of this Section&nbsp;10(b)&nbsp;and the Internal
Revenue Service determines thereafter that some portion of the Payment is subject to the Excise Tax, you shall promptly return to the
Company a sufficient amount of the Payment (after reduction pursuant to clause (x)&nbsp;of the first paragraph of this this Section&nbsp;10(b)&nbsp;so
that no portion of the remaining Payment is subject to the Excise Tax. For the avoidance of doubt, if the Reduced Amount was determined
pursuant to clause (y)&nbsp;in the first paragraph of this this Section&nbsp;10(b), you shall have no obligation to return any portion
of the Payment pursuant to the preceding sentence.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>11.</B></FONT><B>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Other</FONT></B><FONT STYLE="font-size: 10pt">.
As a condition of your commencement of employment hereunder, you must execute and deliver to the Company the Proprietary Information
and Invention Assignment Agreement delivered to you under separate cover (the &ldquo;<U>PIIA</U>&rdquo;), which (among other provisions)
prohibits any unauthorized use or disclosure of Company proprietary, confidential or trade secret information. The parties hereto acknowledge
and agree that this Agreement and the PIIA shall be considered separate contracts, and the PIIA will survive the termination of this
Agreement for any reason.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>12.</B></FONT><B>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Entire
Agreement</FONT></B><FONT STYLE="font-size: 10pt">. This Agreement, together with your PIIA, sets forth our entire agreement and understanding
regarding the terms of your employment with the Company and supersedes any prior representations or agreements, whether written or oral.
This Agreement may not be modified in any way except in a writing signed by the Company&rsquo;s Chief Executive Offer (or another duly
authorized officer of the Company) upon due authorization by the Board or its compensation committee and you. It shall be governed by
California law, without regard to principles of conflicts of laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Signatures are on the following page)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">IN WITNESS WHEREOF, the parties have executed this Agreement as of
the date set forth below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Sincerely,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; width: 50%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Deborah Birx&nbsp;</FONT></TD>
    <TD STYLE="text-align: right; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deborah
    Birx, M.D.&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">ACCEPTED AND AGREED:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: left; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    David House&#8239;&#8239;&#8239;&#8239;&nbsp;</FONT></TD>
    <TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>7/31/24&nbsp;</U></FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">David
    House&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SVP,
    Finance</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date</FONT></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>[Signature Page&nbsp;to D. House Employment
Agreement]</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>3
<FILENAME>tm2421653d1_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: right; margin: 0"><B>Exhibit 99.1</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"><IMG SRC="tm2421653d1_ex99-1img01.jpg" ALT="">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Armata Pharmaceuticals Announces Appointment
of Life Sciences Accounting and Finance Veteran David House as SVP of Finance and Principal Financial Officer</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">LOS ANGELES, Calif., August&nbsp;15, 2024 -- Armata
Pharmaceuticals,&nbsp;Inc. (NYSE American: ARMP) (&ldquo;<I>Armata</I>&rdquo; or the &ldquo;<I>Company</I>&rdquo;), a biotechnology company
focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat
bacterial infections, today announced the appointment of life sciences accounting and finance veteran David House as Senior Vice President,
Finance, effective August&nbsp;16<SUP>th</SUP>. Armata&rsquo;s Corporate Controller, Richard Rychlik, will retain the position of Controller.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;We are delighted to welcome David to the
Armata team,&rdquo; stated Dr.&nbsp;Deborah Birx, Chief Executive Officer of Armata. &ldquo;David&rsquo;s extensive experience and track
record of serving in senior accounting and finance roles within both clinical and commercial stage life sciences companies will serve
us well as we continue to advance our two distinct programs &ndash; AP-PA02 and AP-SA02 &ndash; and prepare to initiate pivotal studies
next year. This is an exciting time at Armata, and the addition of David to our senior team helps ensure that we are best positioned to
achieve long-term success as we work to introduce an exciting new class of anti-infectives to treat serious drug-resistant bacterial infections.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Before joining Armata, Mr.&nbsp;House served as
Corporate Controller and Vice President of Accounting at ZO Skin Health,&nbsp;Inc., a multi-channel physician-dispensed skincare company,
from October&nbsp;2018 to May&nbsp;2024. At ZO Skin Health, he led global accounting operations, managed financial reporting, and played
a crucial role in the company's acquisition by Blackstone. He also established international subsidiaries and oversaw financial integration
for mergers and acquisitions. Mr.&nbsp;House's experience includes similar financial leadership roles at Peregrine Pharmaceuticals,&nbsp;Inc.,
a clinical-stage biopharmaceutical company, and Avid Bioservices,&nbsp;Inc. (CDMO), a contract development and manufacturing organization
where he served as Controller and was responsible for implementing ASC 606, managing technical accounting, and conducting Securities and
Exchange Commission (the &ldquo;<I>SEC</I>&rdquo;) reporting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Mr.&nbsp;House&rsquo;s career also includes roles
at Viant,&nbsp;Inc. (DSP), Sourcing Solutions, LLC, and Apria Healthcare (APR), where he held various accounting and financial management
positions. In the early stages of his career, Mr.&nbsp;House worked as a Senior Auditor at Windes, a public accounting firm. There, he
managed comprehensive audits for public, private, and not-for-profit entities and contributed to SEC filings and internal control evaluations.
Mr.&nbsp;House holds a Bachelor of Arts in Business Administration with an Accounting concentration from California State University,
Fullerton. He obtained his California Certified Public Accountant license, which is currently inactive.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About Armata Pharmaceuticals,&nbsp;Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Armata is a clinical-stage biotechnology company
focused on the development of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat
bacterial infections using its proprietary bacteriophage-based technology. Armata is developing and advancing a broad pipeline of natural
and synthetic phage candidates, including clinical candidates for <I>Pseudomonas aeruginosa</I>, <I>Staphylococcus aureus</I>, and other
pathogens. Armata is committed to advancing phage therapy with drug development expertise that spans bench to clinic including in-house
phage specific cGMP manufacturing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="tm2421653d1_ex99-1img01.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Forward Looking Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This communication contains &ldquo;forward-looking&rdquo;
statements as defined by the Private Securities Litigation Reform Act of 1995. These statements relate to future events, results or to
Armata&rsquo;s future financial performance and involve known and unknown risks, uncertainties and other factors which may cause Armata&rsquo;s
actual results, performance or events to be materially different from any future results, performance or events expressed or implied by
the forward-looking statements. In some cases, you can identify these statements by terms such as &ldquo;anticipate,&rdquo; &ldquo;believe,&rdquo;
&ldquo;could,&rdquo; &ldquo;estimate,&rdquo; &ldquo;expect,&rdquo; &ldquo;intend,&rdquo; &ldquo;may,&rdquo; &ldquo;plan,&rdquo; &ldquo;potential,&rdquo;
&ldquo;predict,&rdquo; &ldquo;project,&rdquo; &ldquo;should,&rdquo; &ldquo;will,&rdquo; &ldquo;would&rdquo; or the negative of those terms,
and similar expressions. These forward-looking statements reflect management&rsquo;s beliefs and views with respect to future events and
are based on estimates and assumptions as of the date of this communication and are subject to risks and uncertainties including risks
related to Armata&rsquo;s development of bacteriophage-based therapies; ability to staff and maintain its production facilities under
fully compliant current Good Manufacturing Practices; ability to meet anticipated milestones in the development and testing of the relevant
product; ability to be a leader in the development of phage-based therapeutics; ability to achieve its vision, including improvements
through engineering and success of clinical trials; ability to successfully complete preclinical and clinical development of, and obtain
regulatory approval of its product candidates and commercialize any approved products on its expected timeframes or at all; and Armata&rsquo;s
estimates regarding anticipated operating losses, capital requirements and needs for additional funds. Additional risks and uncertainties
relating to Armata and its business can be found under the caption &ldquo;Risk Factors&rdquo; and elsewhere in Armata&rsquo;s filings
and reports with the SEC, including in Armata&rsquo;s Annual Report on Form&nbsp;10-K, filed with the SEC on March&nbsp;21, 2024, and
in its subsequent filings with the SEC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Armata expressly disclaims any obligation or undertaking
to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Armata&rsquo;s
expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Media Contacts:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>At Armata:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pierre Kyme</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Armata Pharmaceuticals,&nbsp;Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">ir@armatapharma.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">310-665-2928 x234</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Investor Relations:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Joyce Allaire</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">LifeSci Advisors, LLC</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">jallaire@lifesciadvisors.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">212-915-2569</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>armp-20240731.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.23a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: +aA5w7xRiXgen8uLa3ZcWayLubOdzZR+mYkxtmB7bemK3y0u6qA6eyoqId22YZ0B -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:srt-types="http://fasb.org/srt-types/2023" xmlns:armp="http://armatapharma.com/20240731" elementFormDefault="qualified" targetNamespace="http://armatapharma.com/20240731">
    <annotation>
      <appinfo>
        <link:roleType roleURI="http://armatapharma.com/role/Cover" id="Cover">
          <link:definition>00000001 - Document - Cover</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:linkbaseRef xlink:type="simple" xlink:href="armp-20240731_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="armp-20240731_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" />
    <import namespace="http://fasb.org/us-gaap/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd" />
    <import namespace="http://fasb.org/us-types/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2023" schemaLocation="https://xbrl.sec.gov/country/2023/country-2023.xsd" />
    <import namespace="http://fasb.org/srt/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd" />
    <import namespace="http://fasb.org/srt-types/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>armp-20240731_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.23a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>armp-20240731_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.23a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://armatapharma.com/role/Cover" xlink:href="armp-20240731.xsd#Cover" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://armatapharma.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>tm2421653d1_ex10-1img001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2421653d1_ex10-1img001.jpg
M_]C_X  02D9)1@ ! 0$ R #(  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !V ,4# 2(  A$! Q$!_\0
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M0D#:=';ZE;R)*NS,#W)_,3XF7G[:M[\.?#6LPK\"/AY^T5#X@UM?BUXJTI/
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M6B0'Q%X;2_637=2?P_HT,]N;S5[2#SRY6R\$_$W^P-/T[X;>!?AW\8M$T_\
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MO:C!?:SI$"^)_BWKMI9:;K=QIEO)I&IZ_8?!;2+CP<?!/CZ]U>PTK4;;Q/\
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M1J<X)_N-K/@;POJ]MH5M=Z4WD^%]3@U?18K*:ZC6WU"-6D6258F&]/,D<NC
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EHVEY,8! /SD$Y(P,*"BBMN2*TY8Z:;+_ ",Y2DVVV[MO\S__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>tm2421653d1_ex99-1img01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2421653d1_ex99-1img01.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !! &\# 2(  A$! Q$!_\0
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M>OX_Y[>E3:?JDB, ^=H[E3@#Z?YXQW-;6IWVGV*(;^:.)7)"[N]0BZTL:?\
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# ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140002119809824">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Jul. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jul. 31,  2024<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-37544<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">ARMATA PHARMACEUTICALS, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000921114<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">91-1549568<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">WA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">5005 McConnell Avenue<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Los Angeles<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">90066<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">310<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">655-2928<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ARMP<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSEAMER<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>11
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M<F]P<R]A<' N>&UL4$L! A0#%     @ !H@/6:N=E63N    *P(  !$
M         ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ !H@/
M69E<G",0!@  G"<  !,              ( !S $  'AL+W1H96UE+W1H96UE
M,2YX;6Q02P$"% ,4    "  &B ]9@U.O.4$$  !O$   &
M@($-"   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @ !H@/
M69^@&_"Q @  X@P   T              ( !A P  'AL+W-T>6QE<RYX;6Q0
M2P$"% ,4    "  &B ]9EXJ[',     3 @  "P              @ %@#P
M7W)E;',O+G)E;'-02P$"% ,4    "  &B ]9JL0B%C,!   B @  #P
M        @ %)$   >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ !H@/620>
MFZ*M    ^ $  !H              ( !J1$  'AL+U]R96QS+W=O<FMB;V]K
M+GAM;"YR96QS4$L! A0#%     @ !H@/6660>9(9 0  SP,  !,
M     ( !CA(  %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&      D "0 ^ @
&V!,

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.2.u1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="tm2421653d1_8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://armatapharma.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>armp-20240731.xsd</File>
    <File>armp-20240731_lab.xml</File>
    <File>armp-20240731_pre.xml</File>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="tm2421653d1_8k.htm">tm2421653d1_8k.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>17
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "tm2421653d1_8k.htm": {
   "nsprefix": "armp",
   "nsuri": "http://armatapharma.com/20240731",
   "dts": {
    "schema": {
     "local": [
      "armp-20240731.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "armp-20240731_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "armp-20240731_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "tm2421653d1_8k.htm"
     ]
    }
   },
   "keyStandard": 22,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2023": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 59,
   "unitCount": 3,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2023": 22
   },
   "report": {
    "R1": {
     "role": "http://armatapharma.com/role/Cover",
     "longName": "00000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "AsOf2024-07-31",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tm2421653d1_8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-07-31",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tm2421653d1_8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://armatapharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://armatapharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://armatapharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://armatapharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://armatapharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CountryRegion",
     "presentation": [
      "http://armatapharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://armatapharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://armatapharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://armatapharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r13",
      "r14"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://armatapharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://armatapharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://armatapharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://armatapharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://armatapharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://armatapharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://armatapharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://armatapharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://armatapharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://armatapharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://armatapharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://armatapharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://armatapharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://armatapharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://armatapharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://armatapharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://armatapharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://armatapharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://armatapharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://armatapharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://armatapharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://armatapharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://armatapharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://armatapharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Elected Not To Use the Extended Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://armatapharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://armatapharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://armatapharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://armatapharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://armatapharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://armatapharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://armatapharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://armatapharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://armatapharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://armatapharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://armatapharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://armatapharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Extension",
     "presentation": [
      "http://armatapharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://armatapharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://armatapharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://armatapharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://armatapharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://armatapharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://armatapharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12gTitle",
     "presentation": [
      "http://armatapharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://armatapharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://armatapharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://armatapharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://armatapharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://armatapharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r9": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r10": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Section": "14a",
   "Number": "240",
   "Subsection": "12"
  },
  "r11": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r12": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r13": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r14": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r15": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r16": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r17": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r18": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r19": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>18
<FILENAME>0001104659-24-090153-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001104659-24-090153-xbrl.zip
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M #5Y2-3SX#V4@'JWL/38;C(#B -"I]LA0) (0LTHGR M:,3X,ZL][C!G6S$
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M\&$?V$-"/60Z)KSHT=!NTV'<%7(H<I2<L]8F*O9_*5%@Z#MB*'*4-+3&8L/
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M!?_[1S8=7@^H+=DC(.W$(!TZL!"S)H 2U&X[%IN>L-EU"?[5RH9A5!X.=NL
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M4-MK";"$9+;>!'X'X ZG=YJ(1QKM\I+1_D%"V*^O8\Z=M!7LN$!6^POWUCO
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M94"1U\.T&YC1NGIH[+TARI=0:5K?U:DK/'>@.,5FOH^E,$/!=.)\"5PC>I$
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MC[B&)_AS"\5S=&<P(,#H!MY.3.$)6"UI+E*#\"DXR%568?BIF&/,P7GF5MT
M*I("13>+<%>GH-.3!)6B<2;Q6!<&@U>,SAJC$++0]>IB:U,3NYE6]0%@6AOR
MF$?*/=A8@77U,6J!PO\>T'XNDPJ4TZU,$\PS2UIC:O)01R. *=(7WMFC/22#
MW4T<J(TZ0H=/>#X:3P:^';E9>0$\&SBYN#9\S7Y>A_*LZB6_$S4R_5W>*$4[
M0^]\LV[HDWL'I!.5JC%H^T]A8>>R #'0.0JBM3&&=GA@80P@!'\59*W*N=0)
M05C;Z,O(]C <&U0N7F:B#HEF\+)3B!R$TW38X754B.)=QKN$,S1ONWQ,W>W^
MMGS&;TM2G]Z[I!Z76[^!T/5[YSYL]Q$*]#I$>@0XIV5DN86R;/6+<T8*4+DD
M;*!;,>"G-,7SR-0O&A%;$B=V@E#N47""T"09](BA4YUC"(9$''8L8DA&ST6C
M1U9R-! $FZ&4A;7]S$B">_-MR=V/]RYWUW9O;TEX=('D.W*:TUHVK)_5"EXW
MK;08=28YE5,YIZP'L%#%+ WX( BA ECC+R+&+E3D&64$6'''+MX.,F<B\"NM
MXPJBF<( "0$CS]H, :.HX;_ )# ZQACU-IA_+-)S%]V_=34=H?A"3<#4392I
MS0CP<0Q&!=%Q-Q7X[<&@48,@ME)RN5@.;A*8CT8%QM6'<#8J=/UCL)NLVUOE
M%(PDZZ*.(Z"1Q'2$4R84O<_SQ)K5+KY);\L/C8CE4FK2TO &M,Z$SWHK2?F9
M3^OU\<G+<W%Z_O+EY?'9V<7K7W_>V-V@OZ\NCT_=W[]=G%V_^'EC;W?W'QM_
ME8([BC\.K]^ZD<$NIARUPP!X$6M\#J_/W!,W.BZG-0SL7)\=K?[VY.@G"P/-
MQSJ3[/#T%8AK@6B*+W%.S-N[WF!Q&2[C'JZ-E5B!DM=#%R[6F*L<69V/%.Q<
MO\5_(./_QA"\=S< 2R>^7QYV+U(V[QAY?$*O82LZK6LZ<0@UYBEJ3#&@2.68
MPY0*/&;V5$BEEU.P!>)*V4A> 0]*UKI@ZDG*LBTP$]E($")ZUCJ_/3E*UJ]9
M%HNW!'3+TV]&S;@ONIYL8(P0X0">_'H;TR)8 E="""ZL+G!1.O!9=5E16L:!
ME%%@F >Q0.O_.HLGI(YB N(: ;H"C'U+"1]ZTQX &]7<?KS[['AK;S!%SCA>
M,](SZBXPTJP*)&NN>'BN.L%5*IHFJBD$&+UJ$7G%1#9B"X.VLF@M/T+7/1CS
M(IUG2966J"X:6CP8DY-7,.R*AT6< 2\QB9N-1I2*+5RXY52?BLLB*YDSXA*.
M(>PYL+/?:^\VJE[V8.+8\H'=[0[M$84N.8E65G^)8S2VXJ?!R H'S<7FA .[
M?@]#-V7")H6->%,.A"/_/F%@] <Q>&H'FL%1G!JOW<EL@*47*-JA!AX WS/B
M!NYWK##?;,A["I_"U':_AY%KPQZA--JTC\BFT\&H=&L]W-"[9-KXE&+$X7<;
M^S C\/<J=,]"Y+Z-4?U>2X][G2$NY>++:O O$_#>_Q[P_FH"WFNH[N%#4=U4
MVX*HI#[DL%Q%F<-T-=[6 )M;1&W5-G;!;@/3,3H*T\ PH+934/][(;+9RB4+
MP*@QJ]G,.S1UD/<4#(,)P9FM$6MHRC:\/+-8C^.RIFC$YL/JC3.JR@$T4RDB
M6R-^2\P"?"QO5#)'RO<WA<5C#8L"IZQ4R:(5]V^O@?39$OE6"X$_N)8::I=U
MX&.A(FH4<:ZODH332" B/&B]%IN!YJF],=ZQ_2NQ^GE0^;6LY3J8FHUMT1OR
M9JM#RWT9Q43V(*@D;^E9WL"91WIR/!]ER2'-@(Q$WM3Q(ZI02,'L6OBD=*.$
MK[VAO&S (9 GE=C3A.4.;T[>'O=[-F'B[$ID.(@3&XA=T=$).-FYF"JL,*!8
M;-3,F=CB(9C,\20681T1%3Y+$%P^I&@@2(L [+ O;UY;,I#P#CQHAA0HU (3
M1XT2S8R*GCC(H$!4QU&'F<2H1I/#6SQ=7JB9KF; (<.&O\TV67[5YNZ!.+PX
M<A;_X<[%4<2'G8#."3X5"LK4'CC @5'"#DSM N Y@MTA4TL!/[7S85A><ETT
ML"QDB@MLU[@<->S9X-%(##X$OLY0 ::NJI\ IMIM=V<63=U14L4\,D=?I#!Y
M!FOQ N,BK51ZN0@FP^J--!-)!OA5-/UU#PHLAT3QP[?//I%&']V?1K]&#=9
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M?D',N4A3$):Y#._?H72N];U8D_]!-LY6=D->CR^I==Z\'(_!U*':-<]5M%M
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M2%BT?6:QKD<RX72'U?V:QI(L$:_4(%?H _QO;&(T!S>1%3HM%&>H"RY1&ZZ
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MEOZ*]E]02P$"% ,4    "  &B ]9SK9%2"P#  #O"P  $0
M@ $     87)M<"TR,#(T,#<S,2YX<V102P$"% ,4    "  &B ]9E8SM0_T*
M  " A@  %0              @ %; P  87)M<"TR,#(T,#<S,5]L86(N>&UL
M4$L! A0#%     @ !H@/60DB3(!9!P  W5<  !4              ( !BPX
M &%R;7 M,C R-# W,S%?<')E+GAM;%!+ 0(4 Q0    (  :(#UD$>_JQL1H
M "V"   2              "  1<6  !T;3(T,C$V-3-D,5\X:RYH=&U02P$"
M% ,4    "  &B ]9'#L,&J4>  ! C0  %@              @ 'X,   =&TR
M-#(Q-C4S9#%?97@Q,"TQ+FAT;5!+ 0(4 Q0    (  :(#UDC.F<8*@T  $PK
M   6              "  =%/  !T;3(T,C$V-3-D,5]E>#DY+3$N:'1M4$L%
3!@     &  8 C0$  "]=      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>tm2421653d1_8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="armp-20240731.xsd" xlink:type="simple"/>
    <context id="AsOf2024-07-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
        </entity>
        <period>
            <startDate>2024-07-31</startDate>
            <endDate>2024-07-31</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:AmendmentFlag contextRef="AsOf2024-07-31" id="Fact000003">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="AsOf2024-07-31" id="Fact000004">0000921114</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="AsOf2024-07-31" id="Fact000009">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="AsOf2024-07-31" id="Fact000010">2024-07-31</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="AsOf2024-07-31" id="Fact000011">ARMATA PHARMACEUTICALS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="AsOf2024-07-31" id="Fact000012">WA</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="AsOf2024-07-31" id="Fact000013">001-37544</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="AsOf2024-07-31" id="Fact000014">91-1549568</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="AsOf2024-07-31" id="Fact000015">5005 McConnell Avenue</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="AsOf2024-07-31" id="Fact000016">Los Angeles</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="AsOf2024-07-31" id="Fact000017">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="AsOf2024-07-31" id="Fact000018">90066</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="AsOf2024-07-31" id="Fact000019">310</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="AsOf2024-07-31" id="Fact000020">655-2928</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="AsOf2024-07-31" id="Fact000021">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="AsOf2024-07-31" id="Fact000022">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="AsOf2024-07-31" id="Fact000023">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="AsOf2024-07-31" id="Fact000024">false</dei:PreCommencementIssuerTenderOffer>
    <dei:EntityEmergingGrowthCompany contextRef="AsOf2024-07-31" id="Fact000025">false</dei:EntityEmergingGrowthCompany>
    <dei:Security12bTitle contextRef="AsOf2024-07-31" id="Fact000026">Common Stock</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="AsOf2024-07-31" id="Fact000027">ARMP</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="AsOf2024-07-31" id="Fact000028">NYSEAMER</dei:SecurityExchangeName>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
